Striessnig J, Murphy B J, Catterall W A
Department of Pharmacology, University of Washington, Seattle 98195.
Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10769-73. doi: 10.1073/pnas.88.23.10769.
To identify the binding domain for dihydropyridine Ca2+ antagonists, skeletal muscle Ca2+ channels were photolabeled with 3H-PN200-110 and [3H]azidopine. Regions of alpha 1 photolabeled by these ligands were then identified by antibody mapping of proteolytic fragments. Approximately 50% of the specific labeling by both ligands was incorporated in domain III. [3H]Azidopine labeled peptide Gln-989-Arg-1022, which contains a portion of the connecting loop between transmembrane segments IIIS5 and IIIS6 (IIIS5/S6), and peptide Ala-1023-Lys-1077, which contains IIIS6 itself and some adjacent amino acid residues. In contrast, 3H-PN200-110 labeling occurred almost exclusively in the fragment containing IIIS6. A second site labeled by both ligands was identified in transmembrane segment S6 of domain IV and adjacent residues. In contrast to azidopine, the photoreactive benzofurazane group of (+)-PN200-110 is located in close proximity to the essential dihydropyridine ring. Therefore, the regions photolabeled by 3H-PN200-110 within or adjacent to transmembrane segments IIIS6 and IVS6 must participate in the formation of the dihydropyridine binding site. As IIIS5/S6 is preferentially labeled by [3H]azidopine, it may contribute to drug binding by interaction with the long side chain of some dihydropyridines like azidopine. It is proposed, based on physiological studies, that these three peptide segments interact to form a receptor site accessible from the extracellular surface of the Ca2+ channel.
为了确定二氢吡啶类钙离子拮抗剂的结合结构域,用3H-PN200-110和[3H]叠氮平对骨骼肌钙离子通道进行光标记。然后通过对蛋白水解片段的抗体定位来确定被这些配体光标记的α1区域。两种配体的特异性标记中约50%掺入了结构域III。[3H]叠氮平标记了肽段Gln-989-Arg-1022,其包含跨膜片段IIIS5和IIIS6(IIIS5/S6)之间连接环的一部分,以及肽段Ala-1023-Lys-1077,其包含IIIS6本身和一些相邻的氨基酸残基。相比之下,3H-PN200-110标记几乎只发生在包含IIIS6的片段中。两种配体标记的第二个位点在结构域IV的跨膜片段S6及其相邻残基中被确定。与叠氮平不同,(+)-PN200-110的光反应性苯并呋喃基团紧邻必需的二氢吡啶环。因此,在跨膜片段IIIS6和IVS6内或其附近被3H-PN200-110光标记的区域必定参与了二氢吡啶结合位点的形成。由于IIIS5/S6优先被[3H]叠氮平标记,它可能通过与某些二氢吡啶(如叠氮平)的长侧链相互作用而有助于药物结合。基于生理学研究提出,这三个肽段相互作用形成一个可从钙离子通道细胞外表面接近的受体位点。